APOE3ch Alleviates Aβ and Tau Pathology and Neurodegeneration in the Human APPNL-G-F Cerebral Organoid Model of Alzheimer’s Disease

Hang Liu,Fan Mei,Rongrong Ye,Xinyu Han,Shudan Wang,Yan Ding,Yun Zhi,Keliang Pang,Wei Guo,Bai Lu

DOI: https://doi.org/10.1038/s41422-024-00957-w

IF: 44.1

2024-01-01

Cell Research

Abstract:Dear Editor, Research in Alzheimer's disease(AD)has greatly benefited from the genetic studies of rare autosomal dominant mutations.1 In a recent case study of the world's largest early onset AD pedigree with presenilin 1(PSEN1)mutation,an individual was identified to have a high amyloid burden but low tau measurements,and an unusually delayed onset of cognitive impairment.2 Whole-exome sequencing revealed an additional rare homozygous mutation of APOE3 Christchurch(APOE3ch,R136S)as the potential protective factor for AD.